ABSTRACT
Mirtazapine (MZPc) is an antidepressant drug which is approved by the FDA. It has low bioavailability, which is only 50%, in spite of its rapid absorption when orally administered owing to high first-pass metabolism. This study was oriented towards delivering intranasal (IN) mirtazapine by a direct route to the brain by means of preparing lipid nanocapsules (LNCs) as a targeted drug delivery system. MZP-LNCs were constructed by solvent-free phase inversion temperature technique applying D-Optimal mixture design to study the impact of 3 formulation variables on the characterization of the formulated nanocapsules. Independent variables were percentage of Labrafac oil, percentage of Solutol and percentage of water. Dependent variables were particle size, polydispersity index (PDI), Zeta potential and solubilization capacity. Nanocapsules of the optimized formula loaded with MZP were of spherical shape as confirmed by transmission electron microscopy with particle diameter of 20.59 nm, zeta potential of - 5.71, PDI of 0.223 and solubilization capacity of 7.21 mg/g. The in vivo pharmacokinetic behavior of intranasal MZP-LNCs in brain and blood was correlated to MZP solution after intravenous (IV) and intranasal administration in mice. In vivo biodistribution of the drug in mice was assessed by a radiolabeling technique using radioiodinated mirtazapine (131I-MZP). Results showed that intranasal MZP-LNCs were able to deliver higher amount of MZP to the brain with less drug levels in blood when compared to the MZP solution after IV and IN administration. Moreover, the percentage of drug targeting efficiency (%DTE) of the optimized MZP-LNCs was 332.2 which indicated more effective brain targeting by the intranasal route. It also had a direct transport percentage (%DTP) of 90.68 that revealed a paramount contribution of the nose to brain pathway in the drug delivery to the brain.
Subject(s)
Administration, Intranasal , Brain , Lipids , Mirtazapine , Nanocapsules , Animals , Mirtazapine/pharmacokinetics , Mirtazapine/administration & dosage , Mirtazapine/chemistry , Brain/metabolism , Tissue Distribution , Nanocapsules/chemistry , Lipids/chemistry , Lipids/pharmacokinetics , Lipids/administration & dosage , Male , Mice , Drug Delivery Systems , Particle Size , Iodine Radioisotopes/pharmacokinetics , Iodine Radioisotopes/administration & dosage , Nasal Mucosa/metabolism , Mianserin/pharmacokinetics , Mianserin/administration & dosage , Mianserin/chemistry , Mianserin/analogs & derivatives , Mianserin/bloodABSTRACT
INTRODUCTION: To investigate the metabolism of mirtazapine (MIR) in Japanese psychiatric patients, we determined the plasma levels of MIR, N-desmethylmirtazapine (DMIR), 8-hydroxy-mirtazapine (8-OH-MIR), mirtazapine glucuronide (MIR-G), and 8-hydroxy-mirtazapine glucuronide (8-OH-MIR-G). METHODS: Seventy-nine Japanese psychiatric patients were treated with MIR for 1-8 weeks to achieve a steady-state concentration. Plasma levels of MIR, DMIR, and 8-OH-MIR were determined using high-performance liquid chromatography. Plasma concentrations of MIR-G and 8-OH-MIR-G were determined by total MIR and total 8-OH-MIR (i. e., concentrations after hydrolysis) minus unconjugated MIR and unconjugated 8-OH-MIR, respectively. Polymerase chain reaction was used to determine CYP2D6 genotypes. RESULTS: Plasma levels of 8-OH-MIR were lower than those of MIR and DMIR (median 1.42 nmol/L vs. 92.71 nmol/L and 44.96 nmol/L, respectively). The plasma levels (median) of MIR-G and 8-OH-MIR-G were 75.00 nmol/L and 111.60 nmol/L, giving MIR-G/MIR and 8-OH-MIR-G/8-OH-MIR ratios of 0.92 and 59.50, respectively. Multiple regression analysis revealed that smoking was correlated with the plasma MIR concentration (dose- and body weight-corrected, p=0.040) and that age (years) was significantly correlated with the plasma DMIR concentration (dose- and body weight-corrected, p=0.018). The steady-state plasma concentrations of MIR and its metabolites were unaffected by the number of CYP2D6*5 and CYP2D6*10 alleles. DISCUSSION: The plasma concentration of 8-OH-MIR was as low as 1.42 nmol/L, whereas 8-OH-MIR-G had an approximate 59.50 times higher concentration than 8-OH-MIR, suggesting a significant role for hydroxylation of MIR and its glucuronidation in the Japanese population.
Subject(s)
Asian People , Glucuronides/blood , Hydroxylation , Mianserin/analogs & derivatives , Mirtazapine/pharmacokinetics , Age Factors , Alleles , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacokinetics , Cytochrome P-450 CYP2D6/genetics , Genotype , Humans , Japan , Mental Disorders/blood , Mianserin/blood , Mirtazapine/analogs & derivatives , Mirtazapine/blood , Smoking/bloodABSTRACT
Postmortem blood samples may not accurately reflect antemortem drug concentrations, as the levels of some drugs increase due to postmortem redistribution (PMR). The brain has been suggested as an alternative sampling site. The anatomically secluded site of the brain limits redistribution and prolongs the detection window, thereby enabling sampling from deceased individuals where blood is no longer suitable for analysis. We report concentrations in brain tissue and blood from 91 cases for the four antidepressants citalopram, duloxetine, mirtazapine and sertraline. The cases were classified according to their role in the cause of death, as follows: (A) concentrations where the drug was the sole cause of fatal intoxication; (B) concentrations where the drug contributed to a fatal outcome; and (C) concentrations where the drug was not related to the cause of death. The analytical method was successfully validated in brain tissue in terms of linearity, process efficiency, precision and accuracy. Quantification of analytes was performed by ultra-performance liquid chromatography with tandem mass spectrometry. Correlations between blood and brain concentrations were achieved with R2-values between 0.67 and 0.91. The following median brain-blood ratios were obtained: 3.71 for citalopram (range: 1.4-5.9), 11.0 for duloxetine (range: 5.0-21.6), 1.53 for mirtazapine (range: 1.02-4.71) and 7.38 for sertraline (range: 3.2-14.2). The S/R ratio of racemic citalopram was the same in brain (0.80) and blood (0.85), whereas the median citalopram/N-desmethylcitalopram ratio was higher in brain (9.1) than blood (4.1). The results of this study may serve as reference concentrations in brain for forensic cases.
Subject(s)
Antidepressive Agents/blood , Brain/metabolism , Citalopram/blood , Drug Overdose/blood , Duloxetine Hydrochloride/blood , Mianserin/analogs & derivatives , Sertraline/blood , Calibration , Cause of Death , Chromatography, Liquid/standards , Drug Overdose/diagnosis , Drug Overdose/mortality , Forensic Toxicology/standards , Humans , Linear Models , Mianserin/blood , Mirtazapine , Reference Standards , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization/standards , Tandem Mass Spectrometry/standardsABSTRACT
BACKGROUND: To uncover pharmacokinetic interactions between venlafaxine and doxepin or mirtazapine in a naturalistic sample. METHODS: A therapeutic drug monitoring database containing plasma concentrations of venlafaxine (VEN) and its active metabolite O-desmethylvenlafaxine (ODVEN) was analyzed. We included 1067 of 1594 patients in the analysis. Three study groups were considered; a group of patients under venlafaxine without confounding medications, V0 (n = 905), a group of patients co-medicated with doxepin, VDOX (n = 25) and a second group, co-medicated with mirtazapine, VMIR, n = 137. Plasma concentrations of VEN, ODVEN and the clinically relevant active moiety, sum of venlafaxine and O-desmethylvenlafaxine (ODVEN) (AM), as well as dose-adjusted plasma concentrations (C/D) were compared. RESULTS: Median concentrations in the doxepin group showed 57.7% and 194.4% higher values for AM and VEN respectively; these differences were statistically significant (p < 0.001 for AM and p = 0.002 for VEN). Similar differences were detected for C/D concentrations of active moiety and VEN (p < 0.001 and p = 0.001) with higher values also in the doxepin group. The ratios ODVEN/VEN were lower in the doxepin group (p < 0.001). A co-medication with mirtazapine did not cause any changes in venlafaxine metabolism. CONCLUSIONS: Higher concentrations for VEN and AM imply an inhibiting effect of doxepin on the metabolism of venlafaxine, although the huge variability of concentrations has to be taken into account. It is recommended to monitor plasma concentrations in combination treatment to avoid problems in safety and efficacy. LIMITATIONS: Despite the large size of our study sample, the naturalistic nature of this data may arise some concerns of information bias potentially resulting from non-standardized data recording.
Subject(s)
Antidepressive Agents, Second-Generation/blood , Cyclohexanols/blood , Desvenlafaxine Succinate/blood , Doxepin/blood , Mianserin/analogs & derivatives , Venlafaxine Hydrochloride/blood , Adult , Antidepressive Agents, Second-Generation/pharmacokinetics , Antidepressive Agents, Second-Generation/therapeutic use , Cyclohexanols/pharmacokinetics , Cyclohexanols/therapeutic use , Databases, Factual , Desvenlafaxine Succinate/pharmacokinetics , Desvenlafaxine Succinate/therapeutic use , Doxepin/pharmacokinetics , Doxepin/therapeutic use , Drug Monitoring , Drug Therapy, Combination , Female , Humans , Male , Mianserin/blood , Mianserin/pharmacokinetics , Mianserin/therapeutic use , Middle Aged , Mirtazapine , Polypharmacy , Venlafaxine Hydrochloride/pharmacokinetics , Venlafaxine Hydrochloride/therapeutic useABSTRACT
Mirtazapine is a noradrenergic and specific serotoninergic antidepressant agent that stimulates norepinephrine and serotonin release while also blocking serotonin receptors (5-HT2 and 5-HT3). Although the drug is used extensively, at present we do not know of any fatal cases due to mirtazapine alone. On the contrary, the published literature describes several fatal poisoning cases related to the intake of mirtazapine together with other drugs. Here we describe a fatal case of mirtazapine self-poisoning, since the other drug detected (lorazepam), was within the therapeutic range. Analyses were performed by LC-MS/MS on body fluids and a hair sample and mirtazapine concentration measured in blood was very high: 9.3mg/L. N-Desmethylmirtazapine was also quantitated. We then compared our results with those of previously published cases. In conclusion, even though mirtazapine can be considered a relatively safe drug, taking a large amount alone or in combination with other drugs, could lead to death.
Subject(s)
Antidepressive Agents, Tricyclic/poisoning , Mianserin/analogs & derivatives , Suicide , Antidepressive Agents, Tricyclic/blood , Chromatography, Liquid , Humans , Male , Mass Spectrometry , Mianserin/blood , Mianserin/poisoning , Middle Aged , MirtazapineABSTRACT
Objectives The objective of this study was to measure drug exposure and clinical effects after administration of transdermal mirtazapine (TMZ) in healthy cats. Methods Phase I: seven healthy research cats received (1) 3.75 mg and 7.5 mg TMZ once aurally with 48 h serum sampling (serum samples were obtained via the jugular catheter at 0, 0.5, 1, 2, 5, 9, 12, 24, 36 and 48 h); (2) 7.5 mg TMZ and placebo daily aurally for 6 days then 48 h serum sampling; (3) 1.88 mg mirtazapine orally once with serum sampling at 1, 4 and 8 h. Phase II: 20 client-owned cats were enrolled in a randomized, double-blind, placebo-controlled, three-way crossover clinical effect study. Treatments consisted of 6 days of aural 7.5 mg TMZ or placebo gel at home, and 1.88 mg mirtazapine orally once in the clinic. Owners documented appetite, rate of food ingestion, begging activity and vocalization daily at home. On day 6, food consumed, activity and vocalization were documented in hospital, and trough and peak serum mirtazapine levels were obtained. Serum mirtazapine and gel concentrations were measured using liquid chromatography/tandem mass spectrometry. Results Phase I: administration of TMZ achieved measureable serum mirtazapine concentrations. Area under the curve0-48 of multidose 7.5 mg TMZ was significantly higher than single-dose 1.88 mg oral mirtazapine (OMZ) ( P = 0.02). Phase II: client-owned cats administered TMZ had a significant increase in appetite ( P = 0.003), rate of food ingestion ( P = 0.002), activity ( P = 0.002), begging ( P = 0.002) and vocalization ( P = 0.002) at home. In hospital there was a significant increase in food ingested with both TMZ and OMZ compared with placebo ( P <0.05). Gel concentrations ranged from 87%-119% of target dose. Conclusions and relevance TMZ 7.5 mg daily achieves measureable serum concentrations and produces significant appetite stimulation despite variance in compounded gel concentrations, but side effects denote a lower dose is indicated.
Subject(s)
Cats/physiology , Mianserin/analogs & derivatives , Administration, Cutaneous , Animals , Appetite/drug effects , Cats/metabolism , Cross-Over Studies , Double-Blind Method , Mianserin/administration & dosage , Mianserin/blood , Mianserin/pharmacokinetics , Mirtazapine , Pilot ProjectsABSTRACT
Fungi colonizing cadavers are capable of drug metabolism and may thus change the metabolite pattern or concentration of drugs in forensic postmortem samples. The purpose of this study was to check for the presence of such changes by searching fungi-specific metabolites of four model drugs (amitriptyline, metoprolol, mirtazapine, and zolpidem) in decomposed postmortem blood samples from 33 cases involving these drugs. After isolation and identification of fungal strains present in the samples, each isolate was incubated in Sabouraud medium at 25°C for up to 120h with each model drug. One part of the supernatants was directly analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), another after liquid-liquid extraction with chlorobutane and concentration. From 21 out of 33 decomposed postmortem blood samples (64%) a total of 30 different strains could be isolated, one from the class of Ascomycete and the rest belonging to 15 species from 8 different genera (number of species): Aspergillus (2), Botrytis (1), Candida (8), Fusarium (1), Mucor (1), Penicillium (1), and Rodothorula (1). In the in vitro studies, these microorganisms were found capable of N-demethylation and N-oxidation of amitriptyline and mirtazapine, O-demethylation followed by side chain oxidation of metoprolol as well as hydroxylation of all four-model drugs. In two of the postmortem blood samples, from which the fungi Aspergillus jensenii, Candida parapsilosis. and Mucor circinelloides had been isolated, a fungi-specific hydroxy zolpidem metabolite was detected. The presence of this metabolite in postmortem samples likely indicates postmortem fungal biodegradation.
Subject(s)
Amitriptyline/blood , Fungi/isolation & purification , Metoprolol/blood , Mianserin/analogs & derivatives , Postmortem Changes , Pyridines/blood , Aged , Biotransformation , Cardiovascular Agents/blood , Central Nervous System Agents/blood , Chromatography, Liquid , Female , Humans , Male , Mianserin/blood , Middle Aged , Mirtazapine , Tandem Mass Spectrometry , ZolpidemABSTRACT
INTRODUCTION: This study evaluated the effects of the CYP2D6*10 genotype on steady-state plasma concentrations of enantiomeric mirtazapine (MIR) and N-desmethylmirtazapine (DMIR) in Japanese patients. METHODS: Subjects were 77 Japanese patients treated with racemic MIR. Steady-state plasma concentrations of MIR and DMIR enantiomers were measured using stereoselective liquid chromatography. Polymerase chain reaction was used to determine the CYP2D6 genotypes. RESULTS: After correcting for dose and body weight, smokers (n=15) had significantly lower S-(+)-MIR than nonsmokers (n=55) (15.1±17.8 vs. 23.9±17.8 ng/mL/mg/kg, Kruskal-Wallis test, p=0.034). One-way analysis of variance revealed that CYP2D6*10 homozygotes had significantly higher corrected plasma concentrations of S-(+)-MIR than the no-variant allele group (p=0.034). Multiple regression analysis revealed a significant positive correlation between the number of CYP2D6*10 alleles and corrected plasma concentrations of S-(+)-MIR. These results yielded the following final model: corrected plasma concentration of S-(+)-MIR=15.9+7.30×(number of CYP2D6*10 alleles) (R=0.279, p=0.023, coefficient of determination (R(2))=0.078). CONCLUSION: Homozygous CYP2D6*10 alleles and smoking have a significant impact on the metabolism of S-(+)-MIR in Japanese patients.
Subject(s)
Antidepressive Agents, Tricyclic/blood , Cytochrome P-450 CYP2D6/genetics , Depressive Disorder/drug therapy , Genotype , Mianserin/analogs & derivatives , Adolescent , Adult , Aged , Aged, 80 and over , Alleles , Antidepressive Agents, Tricyclic/therapeutic use , Depressive Disorder/blood , Depressive Disorder/genetics , Female , Humans , Japan , Male , Mianserin/blood , Mianserin/therapeutic use , Middle Aged , Mirtazapine , Pharmacogenetics , Young AdultABSTRACT
OBJECTIVE: Our study aimed to investigate the effect of mirtazapine on bone metabolism in the orchidectomized rat model. METHODS: Rats were divided into three groups. A sham-operated control group (SHAM group) and a control group after orchidectomy (ORX group) received the standard laboratory diet (SLD). An experimental group after orchidectomy (ORX MIRTA group) received SLD enriched with mirtazapine for 12 weeks. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. Bone marker concentrations of osteoprotegerin (OPG), amino-terminal propeptide of procollagen type I, bone alkaline phosphatase (BALP), sclerostin and bone morphogenetic protein 2 were examined in bone homogenate. The femurs were used for biomechanical testing. RESULTS: Compared with the control ORX group, we found a lower BMD in the ORX MIRTA group. The differences were statistically significant, although not in the lumbar vertebrae. BMD was lower in the MIRTA group, suggesting a preferential effect on cortical bone. However, although the thickness of the diaphyseal cortical bone was not different, the fragility in the femoral neck area was statistically significantly different between the groups in biomechanical testing. Regarding the bone metabolism markers, there was a significant decrease in OPG and BALP levels, suggesting a reduction in osteoid synthesis. CONCLUSIONS: The results suggest that prolonged use of mirtazapine may have a negative effect on the synthesis of bone and on its mechanical strength, especially in the femoral neck. Further studies are warranted to establish whether mirtazapine may have a clinically significant adverse effect on bone exclusively in the model of gonadectomized rats, or whether the effect occurs also in the model of gonadally intact animals and in respective human models.
Subject(s)
Adrenergic alpha-Antagonists/pharmacology , Antidepressive Agents, Tricyclic/pharmacology , Bone and Bones/drug effects , Mianserin/analogs & derivatives , Adrenergic alpha-Antagonists/blood , Adrenergic alpha-Antagonists/pharmacokinetics , Alkaline Phosphatase/metabolism , Animals , Antidepressive Agents, Tricyclic/blood , Antidepressive Agents, Tricyclic/pharmacokinetics , Biomechanical Phenomena , Bone Density/drug effects , Bone and Bones/metabolism , Bone and Bones/physiology , Compressive Strength , Male , Mianserin/blood , Mianserin/pharmacokinetics , Mianserin/pharmacology , Mirtazapine , Orchiectomy , Osteoprotegerin/metabolism , Rats, WistarABSTRACT
RATIONALE: The aim of this study was to investigate the distribution pattern of mirtazapine and its metabolite normirtazapine (N-desmethylmirtazapine) in blood and cerebrospinal fluid (CSF). OBJECTIVES AND METHODS: Concentrations of mirtazapine were measured in blood serum and CSF of 16 patients treated with daily doses of 7.5-60 mg. Daily doses were correlated with serum and CSF concentrations as well as serum levels with those in CSF. RESULTS: Serum levels of mirtazapine and normirtazapine showed a strong relation to the daily dose of mirtazapine of r = +0.631 and r = +0.732, respectively (p < 0.01). Between the daily doses and the CSF levels of both mirtazapine and normirtazapine, we only found a trend-wise correlation (r = +0.535, p = 0.060). The correlation between mirtazapine and normirtazapine in serum and CSF was highly significant (r = +0.664, p = 0.005 and r = +0.885, p < 0.001, respectively). High discrepancies between (total) mirtazapine levels in serum and CSF indicate a low penetration into CSF with regard to the total serum concentration as the mean of the calculated penetration ratio was 0.16 (SD = 0.11). By correcting the penetration ratio for the plasma protein binding, the mean CSF/serum ratio for the unbound fraction was 1.05 (SD 0.72, range 0.56-3.19) indicating a high passage into CSF. CONCLUSIONS: Findings indicate a good ability of mirtazapine and normirtazapine to overcome the blood-cerebrospinal fluid barrier and suggest a high ability to enter the brain with sufficient drug levels at the target sites within the brain contributing to clinical efficacy.
Subject(s)
Mental Disorders/blood , Mental Disorders/cerebrospinal fluid , Mianserin/analogs & derivatives , Adult , Aged , Antidepressive Agents, Tricyclic/administration & dosage , Antidepressive Agents, Tricyclic/blood , Antidepressive Agents, Tricyclic/cerebrospinal fluid , Blood-Brain Barrier/metabolism , Female , Humans , Male , Mental Disorders/drug therapy , Mianserin/administration & dosage , Mianserin/blood , Mianserin/cerebrospinal fluid , Middle Aged , MirtazapineABSTRACT
The present study was designed to estimate the effectiveness of isolation of mirtazapine from the liver, blood, and urine. The conditions were developed for the identification and quantitative measurement of the isolated mirtazapine with the use of high performance liquid chromatography and detection from the UV-spectrum and mass-spectrometry. The retention time of mirtazapine isolated from the liver was 2.88 +/- 0.08 min. The straight-line equation within the range of mirtazapine concentrations from 1 to 20 mc/ml was characterized by the dependence: Y = 3.25 x 10(4)X - 6.27 x 10(3) (r = 0.9997). The study showed that it is possible to isolate 46.44 +/- 1.89% of mirtazapine present in the liver and 50.4 +/- 1.05% from blood using extraction by acetonitrile acidified with an 1 M hydrochloric acid solution. Chloroform extraction from urine at pH 7.0-8.0 releases 90.22 +/- 1.88% of mirtazapine.
Subject(s)
Antidepressive Agents, Tricyclic/analysis , Forensic Toxicology/methods , Liver/chemistry , Mianserin/analogs & derivatives , Antidepressive Agents, Tricyclic/blood , Antidepressive Agents, Tricyclic/urine , Cadaver , Chromatography, High Pressure Liquid , Female , Humans , Liver/metabolism , Liver/pathology , Male , Mass Spectrometry , Mianserin/analysis , Mianserin/blood , Mianserin/urine , Mirtazapine , Sensitivity and SpecificityABSTRACT
INTRODUCTION: Mirtazapine is an antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission. This study aimed to evaluate mirtazapine pharmacokinetic data from Korean psychiatric patients and to identify the potential factors affecting its steady-state concentration. METHODS: A total of 337 samples of steady-state mirtazapine concentrations from 188 adult psychiatric outpatients were retrospectively evaluated. Serum mirtazapine concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry. RESULTS: Median mirtazapine concentration was 43.6 µg/L (164.37 nmol) at a daily dosage range of 7.5-60 mg. At the steady state, mirtazapine dose had a positive correlation with the drug concentration. Mean concentration-to-dose (C/D) ratio was 1.48 µg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects. Age and paroxetine co-medication were positively associated with C/D ratio. Initial mirtazapine concentration and C/D ratio did not show an association with responsiveness in depressive patients. DISCUSSION: This study presented the therapeutic drug monitoring data for mirtazapine and pharmacokinetic variations of mirtazapine in an Asian population. A further study could be helpful for clinical decision making based on the characteristics of patients.
Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Drug Monitoring , Mental Disorders/drug therapy , Mianserin/analogs & derivatives , Outpatients , Adrenergic alpha-Antagonists/blood , Adult , Age Factors , Aged , Dose-Response Relationship, Drug , Female , Humans , Male , Mental Disorders/blood , Mianserin/blood , Mianserin/therapeutic use , Middle Aged , Mirtazapine , Psychiatric Status Rating Scales , Republic of Korea , Retrospective Studies , Treatment OutcomeABSTRACT
A simple, rapid and sensitive chiral capillary zone electrophoresis coupled with acetonitrile-field-amplified sample stacking method was developed that allows the simultaneous enantioselective separation of the mirtazapine, N-demethylmirtazapine, 8-hydroxymirtazapine and mirtazapine-N-oxide. The separation was achieved on an uncoated 40.2 cm×75 µM fused silica capillary with an applied voltage of 16 kV. The electrophoretic analyses were carried out in 6.25 mM borate-25 mM phosphate solution at pH 2.8 containing 5.5 mg/mL carboxymethyl-ß-cyclodextrin. The detection wavelength was 200 nm. Under these optimized conditions, satisfactory chiral separations of four pair enantiomers were achieved in less than 7 min in vitro. After one step clean-up liquid-liquid extraction using 96-well format, sample was introduced capillary zone electrophoresis with acetonitrile-field-amplified sample stacking to enhance the sensitivity of enantiomers. The method was validated with respect to specificity, linearity, lower limit of quantitation, accuracy, precision, extraction recovery and stability. The lower limit of quantification was 0.5 ng/mL with linear response over the 0.5-50 ng/mL concentration range for each mirtazapine, N-demethylmirtazapine and 8-hydroxymirtazapine enantiomer. The developed and validated method has been successfully applied to the enantioselective pharmacokinetic studies in 12 healthy volunteers after oral administration of rac- mirtazapine.
Subject(s)
Antidepressive Agents, Tricyclic/blood , Chemical Fractionation/methods , Electrophoresis, Capillary/methods , Mianserin/analogs & derivatives , Acetonitriles/chemistry , Administration, Oral , Antidepressive Agents, Tricyclic/pharmacokinetics , Biotransformation , Buffers , Cyclic N-Oxides/blood , Humans , Limit of Detection , Male , Mianserin/blood , Mianserin/pharmacokinetics , Mirtazapine , Reproducibility of Results , Stereoisomerism , beta-Cyclodextrins/chemistryABSTRACT
An ultra-performance liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of 25 common pharmaceuticals in whole blood. The selected pharmaceuticals represent the most frequently detected drugs in our forensic laboratory with basic properties such as analgesics, antidepressants, antihistamines, antihypertensives, antipsychotics and ß-blockers. Whole blood samples were extracted with butyl acetate after adjusting pH with 2M NaOH. The target analytes were separated on a 100 × 2.1 mm ACQUITY BEH 1.7 µm C18 column by a formic acid/acetonitrile gradient elution using a Waters ACQUITY Ultra-Performance Liquid Chromatography system. Quantification was performed on a Waters tandem quadrupole ACQUITY TQD using multiple reaction monitoring in positive mode. The analytes were eluted within 11 min. The limit of quantification (LOQ) ranged from 0.002 to 0.01 mg/kg depending on the analyte. A good linear behavior was achieved for all analytes in the range from LOQ to 1.0 or 2.0 mg/kg blood. The absolute recoveries were between 55-87% for all compounds except norfluoxetine (44%). The method showed acceptable precision and accuracy for almost all analytes. Only unstable compounds like levomepromazine, methylphenidate, mirtazapine, norfluoxetine and zuclopenthixol deviated more. The method was successfully applied to more than 200 authentic blood samples within a year from forensic investigations.
Subject(s)
Chromatography, High Pressure Liquid/methods , Pharmaceutical Preparations/blood , Tandem Mass Spectrometry/methods , Analgesics/blood , Antidepressive Agents/blood , Antihypertensive Agents/blood , Antipsychotic Agents/blood , Clopenthixol/blood , Fluoxetine/analogs & derivatives , Fluoxetine/blood , Histamine Antagonists/blood , Humans , Limit of Detection , Linear Models , Methotrimeprazine/blood , Methylphenidate/blood , Mianserin/analogs & derivatives , Mianserin/blood , Mirtazapine , Quality Control , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
A rapid hydrophilic interaction liquid chromatography/positive ion electrospray mass spectrometric assay (HILIC/ESI-MS) was developed, validated and applied to the determination of deferasirox, in human plasma. The sample preparation process involved liquid-liquid extraction of 50 µL plasma sample using ethyl acetate as an extraction solvent. Chromatographic separation was performed on an XBridge-HILIC analytical column (150.0 mm × 2.1 mm i.d., particle size 3.5 µm, 135 Å) under isocratic elution. The mobile phase was composed of a 10% 8.0 mM ammonium acetate water solution pH=5.0, adjusted with formic acid, in a binary mixture of acetonitrile/methanol (50:50, v/v) and pumped at a flow rate of 0.20 mL/min. Quantitation of deferasirox was performed with selected ion monitoring (SIM) in positive ionization mode using electrospray ionization interface. The assay was found to be linear in the concentration range of 0.20-120.0 µg/mL for deferasirox. Intermediate precision was found less than 3.9% over the tested concentration ranges. A run time of less than 6.0 min for each sample made it possible to analyze a large number of human plasma samples per day. The method can be used to support a wide range of clinical studies concerning deferasirox monitoring and it was applied to the analysis of human plasma samples obtained from patients with ß-thalassemia major.
Subject(s)
Benzoates/blood , Chromatography, Liquid/methods , Spectrometry, Mass, Electrospray Ionization/methods , Triazoles/blood , Acetates , Acetonitriles , Adult , Deferasirox , Female , Humans , Hydrophobic and Hydrophilic Interactions , Linear Models , Male , Methanol , Mianserin/analogs & derivatives , Mianserin/blood , Mirtazapine , beta-Thalassemia/bloodABSTRACT
In the present study a simple, fast, sensitive and robust method to quantify mirtazapine in human plasma using quetiapine as the internal standard (IS) is described. The analyte and the IS were extracted from human plasma by a simple protein precipitation with methanol and were analyzed by high-performance liquid chromatography coupled to an electrospray tandem triple quadrupole mass spectrometer (HPLC-ESI-MS/MS). Chromatography was performed isocratically on a C(18), 5 µm analytical column and the run time was 1.8 min. The lower limit of quantitation was 0.5 ng/mL and a linear calibration curve over the range 0.5-150 ng/mL was obtained, showing acceptable accuracy and precision. This analytical method was applied in a relative bioavailability study in order to compare a test mirtazapine 30 mg single-dose formulation vs a reference formulation in 31 volunteers of both sexes. The study was conducted in an open randomized two-period crossover design and with a 14 day washout period. Since the 90% confidence interval for C(max) , AUC(last) and AUC(0-inf) were within the 80-125% interval proposed by the Food and Drug Administration and ANVISA (Brazilian Health Surveillance Agency), it was concluded that mirtazapine 30 mg/dose is bioequivalent to the reference formulation, according to both the rate and extent of absorption.
Subject(s)
Chromatography, High Pressure Liquid/methods , Mianserin/analogs & derivatives , Tandem Mass Spectrometry/methods , Adult , Area Under Curve , Biological Availability , Cross-Over Studies , Dibenzothiazepines/blood , Drug Stability , Female , Humans , Linear Models , Male , Mianserin/blood , Mianserin/chemistry , Mianserin/pharmacokinetics , Middle Aged , Mirtazapine , Quetiapine Fumarate , Sensitivity and Specificity , Spectrometry, Mass, Electrospray Ionization/methodsABSTRACT
Mirtazapine (MRT) is a human antidepressant drug mainly metabolised by the cytochrome P450 enzyme system to 8-OH mirtazapine (8-OH) and dimetilmirtazapine (DMR). The drug is usually administered to dogs with anorexia according to doses extrapolated from humans, although it could also have applications as an antidepressant and analgesic in this species. The aim of this study was to assess the pharmacokinetics of MRT and its metabolites, DMT and 8-OH. Six healthy male Beagle dogs were administered MRT orally (20 mg/dog) and plasma MRT and metabolite concentrations were evaluated by high performance liquid chromatography with fluorescence detection. The pharmacokinetic profiles of MRT and DMR were similar (detected from 0.25 up to 10 h), while 8-OH (detected from 0.50 up to 10 h) attained the highest concentrations. The mean half-life of MRT was 6.17 h with a clearance of 1193 mL/h/kg. The study showed that MRT has a different pharmacokinetic profile in the dog compared to other species.
Subject(s)
Antidepressive Agents, Tricyclic/pharmacokinetics , Mianserin/analogs & derivatives , Administration, Oral , Animals , Antidepressive Agents, Tricyclic/administration & dosage , Antidepressive Agents, Tricyclic/blood , Chromatography, High Pressure Liquid/methods , Chromatography, High Pressure Liquid/veterinary , Dogs/metabolism , Half-Life , Male , Metabolic Clearance Rate , Mianserin/administration & dosage , Mianserin/blood , Mianserin/pharmacokinetics , Mirtazapine , Pilot ProjectsABSTRACT
The purpose of the study was to formulate and evaluate controlled release chitosan microspheres of mirtazapine (MTZ) to improve the bioavailability by altering the pharmacokinetic profiles of the drug. Chitosan microspheres were prepared to prolong the release of the drug into the systemic circulation. Microspheres were prepared by a single water in oil (w/o) emulsion technique varying the chitosan/drug ratio, stirring speed and concentration of the crosslinking agent (glutaraldehyde). Drug-polymer compatibility studies were carried out using fourier transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC). The microspheres were evaluated for encapsulation efficiency, particle size, surface morphology, swelling index, in vitro release, as well as erosion and in vivo studies in rats. The FT-IR and DSC studies revealed no interaction between drug and polymer. The encapsulation efficiency of different formulation varied from 53 ± 1.2% to 78 ± 1.5%. The mean particle size of the optimized formulation F-14 was 106.4 ± 0.5 µm. Surface morphology revealed that chitosan microspheres were discrete and spherical in shape with a porous surface. The release of MTZ from chitosan microspheres was rapid up to 4 h, and then it was continuously and slowly released up to 48 h. Optimized formulation (F-14) was found to be stable under accelerated storage conditions based on International Conference on Harmonisation guidelines. Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 µg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration. Hence, the present study demonstrates that controlled release formulation of MTZ microspheres using chitosan can improve pharmacokinetic profiles of MTZ.
Subject(s)
Antidepressive Agents, Tricyclic/administration & dosage , Antidepressive Agents, Tricyclic/chemistry , Chitosan/chemistry , Mianserin/analogs & derivatives , Microspheres , Animals , Antidepressive Agents, Tricyclic/blood , Antidepressive Agents, Tricyclic/pharmacokinetics , Biological Availability , Chemical Phenomena , Chitosan/metabolism , Cross-Linking Reagents/chemistry , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/analysis , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Drug Compounding , Drug Stability , Glutaral/chemistry , Half-Life , Hot Temperature , Injections, Intramuscular , Male , Metabolic Clearance Rate , Mianserin/administration & dosage , Mianserin/blood , Mianserin/chemistry , Mianserin/pharmacokinetics , Microscopy, Electron, Scanning , Mirtazapine , Rats , Rats, WistarABSTRACT
A 36 year-old man suffering from schizophrenia was found dead in his apartment. Forensic autopsy was performed due to sudden unexpected death but did not yield the cause of death. Histological examination of the heart showed eosinophilic myocarditis (EM) while forensic chemistry showed a raised level of aripripazol. We discuss the risk of sudden cardiac death in patients receiving antipsychotic drugs and the possible connection between raised drug levels and EM, and we emphasise the importance of autopsy and hope for better means in the future of finding patients at risk.
Subject(s)
Antipsychotic Agents/adverse effects , Death, Sudden, Cardiac/etiology , Eosinophilia/chemically induced , Myocarditis/chemically induced , Piperazines/adverse effects , Quinolones/adverse effects , Adult , Antidepressive Agents, Tricyclic/adverse effects , Antidepressive Agents, Tricyclic/blood , Antipsychotic Agents/blood , Aripiprazole , Autopsy , Benzodiazepines/adverse effects , Benzodiazepines/blood , Drug Therapy, Combination , Eosinophilia/complications , Eosinophilia/pathology , Forensic Pathology , Forensic Toxicology , Humans , Male , Mianserin/adverse effects , Mianserin/analogs & derivatives , Mianserin/blood , Mirtazapine , Myocarditis/complications , Myocarditis/pathology , Myocardium/pathology , Olanzapine , Piperazines/blood , Quinolones/blood , Risk FactorsABSTRACT
BACKGROUND: Cats with chronic kidney disease (CKD) often experience inappetence, and may benefit from administration of mirtazapine, an appetite stimulant. The pharmacokinetics of mirtazapine in CKD cats is unknown. HYPOTHESIS: CKD delays the clearance/bioavailability (CL/F) of mirtazapine. ANIMALS: Six CKD cats and 6 age-matched controls (AMC) were enrolled. Two CKD cats each from International Renal Interest Society (IRIS) stage II, III and IV were included. METHODS: Blood samples were collected before and 0.5, 1, 1.5, 2, 4, 8, 24, and 48 hours after a single PO dose of 1.88 mg of mirtazapine. Mirtazapine concentrations were measured by liquid chromatography coupled to tandem mass spectrometry. Non-compartmental pharmacokinetic modeling was performed. RESULTS: Mean age was 11 years (CKD cats) and 10.8 years (AMC cats). Mean serum creatinine concentration ± standard deviation (SD) was 3.8 ± 1.6 mg/dL (CKD) and 1.3 ± 0.4 mg/dL (AMC). Mean half-life ± SD was 15.2 ± 4.2 hours (CKD) and 12.1 ± 1.1 hours (AMC). Mean area under the curve (AUC) ± SD was 770.6 ± 225.5 ng/mLâ¢hr (CKD) and 555.5 ± 175.4 ng/mLâ¢hr (AMC). Mean CL/F ± SD was 0.6 ± 0.1 L/hr/kg (CKD) and 0.8 ± 0.16 L/hr/kg (AMC). A Mann-Whitney test indicated statistically significant differences in AUC (P = 0.01) and CL/F (P = 0.04) between groups. Calculated accumulation factor for 48-hour dosing in CKD cats was 1.15. CONCLUSION: CKD may delay the CL/F of mirtazapine. A single low dose of mirtazapine resulted in a half-life compatible with a 48-hour dosing interval in CKD cats.